Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Tuesday

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of $0.59 per share and revenue of $184.26 million for the quarter.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same period last year, the firm posted $0.45 EPS. Harmony Biosciences's revenue for the quarter was up 19.5% on a year-over-year basis. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Price Performance

Shares of HRMY opened at $28.50 on Tuesday. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of 13.51, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. Harmony Biosciences has a fifty-two week low of $26.47 and a fifty-two week high of $41.61. The firm has a 50-day simple moving average of $32.74 and a 200-day simple moving average of $34.41. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $50.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho raised their price objective on shares of Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday, March 18th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $53.33.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 1,629 shares of the company's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.02, for a total value of $61,934.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders sold 16,529 shares of company stock worth $619,167 in the last ninety days. Insiders own 23.60% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.